Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447743 · ClinicalTrials.gov registry record · Early Phase 1
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
A Early Phase 1 study, sponsored by Michele Staton.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03447743 is a Early Phase 1 study that has completed, run by Michele Staton. The registered enrollment target is 9 participants.
The verdict
NCT03447743, a Early Phase 1 study, has completed, sponsored by Michele Staton.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The overall aim of this R34 proposal is to examine the feasibility, acceptability, and short-term outcomes associated with an innovative service delivery model to increase adherence to extended-release naltrexone (XR-NTX) during the transition from jail to the community for rural individuals with opioid use disorder (OUD). The significance of this study is grounded in the public health emergency associated with the opioid epidemic in rural Appalachia, the increased vulnerability of rural individuals with OUD, and the dearth of available and accessible evidence-based treatment in the region. This study has potential to make a significant contribution to the OUD treatment field by advancing knowledge on innovative service delivery models to increase access to evidence-based treatment to reduce the prevalence of opioid use disorders and related health disparities among hard-to-reach, high-risk, underserved populations.
Interventions
- DRUG XR-NTX community location
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2022-03-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03447743
The ClinicalTrials.gov registry entry for NCT03447743 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michele Staton, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XR-NTX community location is the first listed.
NCT03447743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03447743 about?
NCT03447743 is a clinical study titled "Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder". The overall aim of this R34 proposal is to examine the feasibility, acceptability, and short-term outcomes associated with an innovative service delivery model to increase adherence to extended-release naltrexone (XR-NTX) during the transition from jail to the community for rural individuals with op...
What is the current status of trial NCT03447743?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2019-09-11. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03447743?
The interventions under investigation include: XR-NTX community location (DRUG).
Who is sponsoring clinical trial NCT03447743?
This trial is sponsored by Michele Staton, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.